# MEG-APSU v1.2.1

**Quantum Drug Target Analyzer** — Structure-based quantum vulnerability scoring for enzyme drug targets.

> *"How many drug targets use quantum mechanics?"*
>
> **Answer: 35.7% of FDA-approved enzyme drug targets are quantum-critical.**

MEG-APSU reads a PDB crystal structure and determines in <1 second whether an enzyme drug target relies on quantum mechanical hydrogen tunneling — making classical computational drug design physically incomplete for that target.

---

## The Discovery

We scanned 115 FDA-approved enzyme drug targets and found:

| Classification | Count | Percentage | Implication |
|---|---|---|---|
| **QUANTUM-CRITICAL** | 41 | 35.7% | Classical docking unreliable |
| QUANTUM-MARGINAL | 3 | 2.6% | Minor quantum effects |
| CLASSICAL | 71 | 61.7% | Standard methods OK |

**Withdrawn drug correlation:** 93% of withdrawn/problematic small-molecule enzyme inhibitors target quantum-critical enzymes, compared to 35.7% in the overall pool.

- **Fisher's exact test:** p = 3.76 × 10⁻⁶
- **Odds ratio:** 33.9
- **Enrichment:** 2.6×

This correlation is statistically significant (★★★ p < 0.001) and suggests that unaccounted quantum effects in classical drug design may contribute to late-stage clinical failures.

### Category Breakdown

100% quantum-critical: all P450s (13/13), MAOs (2/2), COX (2/2), LOX (2/2), NOS (3/3), IDH (2/2), HSD (2/2), XO, DHFR, DHODH, COMT, TH, DBH, AKR, LDH, G6PD, SDH, TS, CYP51

0% quantum-critical: all kinases (0/29), PDEs (0/5), proteases (0/9), carbonic anhydrases (0/4), MMPs (0/4), HDACs (0/2), ACEs (0/2)

---

## How It Works

MEG-APSU uses a Lindblad open quantum system solver (RK4 integration) to compute tunneling enhancement for active sites identified from PDB structure:

1. **Parse** — Atom-level PDB parsing with metal, cofactor, and substrate detection
2. **Classify** — Identify catalytic motifs: metal-oxo, heme, NAD/FAD, quinone, folate, SAM, 2-oxoglutarate, pterin, facial triad, Tyr radical, Ser-His-Asp, Zn Lewis acid
3. **Score** — Lindblad master equation computes tunneling enhancement at 310K
4. **Report** — Quantum Vulnerability Score (QVS 0–100), predicted KIE, classification

### Reaction Types

| Type | Barrier (eV) | Typical KIE | Examples |
|---|---|---|---|
| Radical C-H abstraction | 0.65 | 3–81 | P450, LOX, COX, MMO |
| Hydride transfer | 0.50 | 3–15 | ADH, LDH, DHFR, MAO |
| Proton relay | 0.18 | 1–2 | Serine proteases |
| Lewis acid | 0.30 | 1–3 | Zn metalloenzymes |

---

## Validation

### Training Set (59 enzymes)
- 39 positive (literature-confirmed tunneling) + 20 negative (classical)
- **Sensitivity: 100%** (39/39)
- **Specificity: 100%** (20/20)
- **Accuracy: 100%**
- Cohen's d: 5.833 | ROC AUC: 1.000

### Blind Held-Out Test (30 enzymes)
- 16 positive + 14 negative — **none used during development**
- **Sensitivity: 100%** (16/16)
- **Specificity: 100%** (14/14)
- **Accuracy: 100%**
- Cohen's d: 4.401 | ROC AUC: 1.000

**Total: 89 enzymes, 0 errors.**

---

## Novel Predictions

18 FDA drug targets classified QUANTUM-CRITICAL by MEG-APSU with no published KIE measurement. Each is a testable prediction verifiable by deuterium kinetic isotope effect measurement:

| # | Enzyme | PDB | QVS | Predicted KIE | Drug(s) |
|---|---|---|---|---|---|
| 1 | CYP11A1 | 3N9Y | 74.0 | ≈63.5 | aminoglutethimide |
| 2 | CYP11B1 | 6M7X | 60.0 | ≈54.2 | metyrapone, osilodrostat |
| 3 | CYP11B2 | 4DVQ | 58.0 | ≈52.8 | osilodrostat |
| 4 | CYP51A1 | 3JUV | 64.0 | ≈56.9 | fluconazole, voriconazole |
| 5 | IDH1-R132H | 3MAP | 57.0 | ≈9.8 | ivosidenib |
| 6 | IDH2-R140Q | 5I96 | 53.0 | ≈9.3 | enasidenib |
| 7 | nNOS | 4D1N | 74.0 | ≈63.5 | (experimental) |
| 8 | iNOS | 1NSI | 66.0 | ≈58.2 | (experimental) |
| 9 | eNOS | 4D1O | 66.0 | ≈58.2 | (experimental) |
| 10 | AKR1B1 | 1ADS | 47.0 | ≈8.6 | epalrestat |
| 11 | DBH | 4ZEL | 74.0 | ≈63.5 | disulfiram (indirect) |
| 12 | CYP51-fungal | 5TZ1 | 72.0 | ≈62.2 | fluconazole, itraconazole |
| 13 | InhA-Mtb | 2B35 | 49.0 | ≈8.8 | isoniazid |
| 14 | NS5B-HCV | 1NB7 | 60.0 | ≈54.2 | sofosbuvir, dasabuvir |
| 15 | 11β-HSD1 | 2BEL | 49.0 | ≈8.8 | (experimental, diabetes) |
| 16 | 17β-HSD1 | 1FDT | 51.0 | ≈9.1 | (experimental, cancer) |
| 17 | SDH complex | 1NEK | 75.0 | ≈64.2 | (mitochondrial) |
| 18 | DHODH-Pf | 1TV5 | 57.0 | ≈9.8 | DSM265 (antimalarial) |

---

## Usage

```bash
# Build
cargo build --release

# Validate against known enzymes
./target/release/meg-apsu validate        # 59 training enzymes (100%)
./target/release/meg-apsu blind           # 30 held-out blind test (100%)

# FDA drug target scan with correlation analysis
./target/release/meg-apsu drugbank        # 115 FDA targets + Fisher's test
./target/release/meg-apsu drugbank --json # JSON output

# Scan your own targets
./target/release/meg-apsu scan <file.pdb>         # Single file
./target/release/meg-apsu scan <file.pdb> --json  # JSON output
./target/release/meg-apsu batch <directory>        # Scan all PDBs in directory
```

PDB files are automatically downloaded from RCSB and cached in `~/.meg-apsu-pdb-cache/`.

---

## Known Limitations

- **KIE quantification:** Classification accuracy is 100%, but KIE magnitude prediction is approximate (r² = 0.15). The tool reliably answers "does this enzyme use tunneling?" but not yet "how much?"
- **2-site Lindblad model:** The open quantum system solver uses a simplified 2-state model, not a full N-site Hamiltonian
- **PDB quality dependent:** Apo structures (no substrate/cofactor bound) may miss tunneling signatures. Use holo structures when available
- **Correlation ≠ causation:** The withdrawn drug correlation (p = 3.76 × 10⁻⁶) is statistically significant but does not prove that quantum effects caused drug failures. Multiple confounders exist (CYP-mediated toxicity, off-target effects). This finding demands investigation, not conclusion.

---

## Requirements

- Rust 1.75+ (pinned dependencies for compatibility)
- `curl` (for PDB downloads)
- No other dependencies. Pure Rust. No ML frameworks. No GPU.

---

## How to Cite

If you use MEG-APSU in your research:

```
sectio-aurea-q. (2026). MEG-APSU: Structure-Based Quantum Vulnerability Scoring
reveals 35.7% of FDA drug targets exhibit quantum tunneling signatures.
MEGALODON Research. https://github.com/sectio-aurea-q/meg-apsu
```

---

## Contact

- **Email:** meg.depth@proton.me
- **GitHub:** [sectio-aurea-q](https://github.com/sectio-aurea-q)
- **Web:** [sectio-aurea-q.github.io](https://sectio-aurea-q.github.io)

---

## License

MIT License. See [LICENSE](LICENSE) for details.

---

*Built on a €150 eBay MacBook. For the nature that computes with quantum mechanics in every living cell.*

*sectio-aurea-q · MEGALODON Research · 2026*
